Novel Autoantibodies in Idiopathic Small Fiber Neuropathy.
Options
BORIS DOI
Date of Publication
January 2022
Publication Type
Article
Division/Institute
Author
Chan, Amanda C Y | |
Wong, Hiu Yi | |
Chong, Yao Feng | |
Lai, Poh San | |
Teoh, Hock Luen | |
Ng, Alison Y Y | |
Hung, Jennifer H M | |
Chan, Yee Cheun | |
Ng, Kay W P | |
Vijayan, Joy | |
Ong, Jonathan J Y | |
Chandra, Bharatendu | |
Tan, Chi Hsien | |
Rutt, Nurul H | |
Tan, Ti Myen | |
Ismail, Nur Hafiza | |
Schwarz, Herbert | |
Choi, Hyungwon | |
Sharma, Vijay K | |
Mak, Anselm |
Subject(s)
Series
Annals of neurology
ISSN or ISBN (if monograph)
0364-5134
Publisher
Wiley-Blackwell
Language
English
Publisher DOI
PubMed ID
34761434
Description
OBJECTIVE
Small fiber neuropathy (SFN) is clinically and etiologically heterogeneous. Although autoimmunity has been postulated to be pathophysiologically important in SFN, few autoantibodies have been described. We aimed to identify autoantibodies associated with idiopathic SFN (iSFN) by a novel high-throughput protein microarray platform that captures autoantibodies expressed in the native conformational state.
METHODS
Sera from 58 SFN patients and 20 age- and gender-matched healthy controls (HCs) were screened against >1,600 immune-related antigens. Fluorescent unit readout and postassay imaging were performed, followed by composite data normalization and protein fold change (pFC) analysis. Analysis of an independent validation cohort of 33 SFN patients against the same 20 HCs was conducted to identify reproducible proteins in both cohorts.
RESULTS
Nine autoantibodies were screened with statistical significance and pFC criteria in both cohorts, with at least 50% change in serum levels. Three proteins showed consistently high fold changes in main and validation cohorts: MX1 (FC = 2.99 and 3.07, respectively, p = 0.003, q = 0.076), DBNL (FC = 2.11 and 2.16, respectively, p = 0.009, q < 0.003), and KRT8 (FC = 1.65 and 1.70, respectively, p = 0.043, q < 0.003). Further subgroup analysis into iSFN and SFN by secondary causes (secondary SFN) in the main cohort showed that MX1 is higher in iSFN compared to secondary SFN (FC = 1.61 vs 0.106, p = 0.009).
INTERPRETATION
Novel autoantibodies MX1, DBNL, and KRT8 are found in iSFN. MX1 may allow diagnostic subtyping of iSFN patients. ANN NEUROL 2021.
Small fiber neuropathy (SFN) is clinically and etiologically heterogeneous. Although autoimmunity has been postulated to be pathophysiologically important in SFN, few autoantibodies have been described. We aimed to identify autoantibodies associated with idiopathic SFN (iSFN) by a novel high-throughput protein microarray platform that captures autoantibodies expressed in the native conformational state.
METHODS
Sera from 58 SFN patients and 20 age- and gender-matched healthy controls (HCs) were screened against >1,600 immune-related antigens. Fluorescent unit readout and postassay imaging were performed, followed by composite data normalization and protein fold change (pFC) analysis. Analysis of an independent validation cohort of 33 SFN patients against the same 20 HCs was conducted to identify reproducible proteins in both cohorts.
RESULTS
Nine autoantibodies were screened with statistical significance and pFC criteria in both cohorts, with at least 50% change in serum levels. Three proteins showed consistently high fold changes in main and validation cohorts: MX1 (FC = 2.99 and 3.07, respectively, p = 0.003, q = 0.076), DBNL (FC = 2.11 and 2.16, respectively, p = 0.009, q < 0.003), and KRT8 (FC = 1.65 and 1.70, respectively, p = 0.043, q < 0.003). Further subgroup analysis into iSFN and SFN by secondary causes (secondary SFN) in the main cohort showed that MX1 is higher in iSFN compared to secondary SFN (FC = 1.61 vs 0.106, p = 0.009).
INTERPRETATION
Novel autoantibodies MX1, DBNL, and KRT8 are found in iSFN. MX1 may allow diagnostic subtyping of iSFN patients. ANN NEUROL 2021.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
Chan__2021__Novel_Antibodies.pdf | text | Adobe PDF | 2.58 MB | published |